BRAF and neuroendocrine carcinoma: The combination of a BRAF and EGFR inhibitor was recently approved for metastatic colorectal adenocarcinoma (Van Cutsem et al. 2019), and case reports have shown the benefit of such treatment in CR-NEC (Klempner et al. 2016).